The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.
Karim Fizazi
No relevant relationships to disclose
Lance C. Pagliaro
No relevant relationships to disclose
Aude Flechon
No relevant relationships to disclose
Jozef Mardiak
No relevant relationships to disclose
Lionnel Geoffrois
No relevant relationships to disclose
Pierre Kerbrat
No relevant relationships to disclose
Christine Chevreau
No relevant relationships to disclose
Remy Delva
No relevant relationships to disclose
Frederic Rolland
No relevant relationships to disclose
Christine Theodore
No relevant relationships to disclose
Guilhem Roubaud
No relevant relationships to disclose
Gwenaelle Gravis
No relevant relationships to disclose
Jean-Christophe Eymard
No relevant relationships to disclose
Jean-pierre Malhaire
No relevant relationships to disclose
Claude Linassier
No relevant relationships to disclose
Muriel Habibian
No relevant relationships to disclose
Florence Journeau
No relevant relationships to disclose
Christopher Logothetis
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose
Agnes Laplanche
No relevant relationships to disclose